Although these pathways were significantly downregulated in CD34+ cells from CML patients at seven days post-IM therapy, Notch signalling remained upregulated in both pre- and seven days post-IM therapy (Fig 9b). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.